ALL-SCT BFM International- HSCT in Children and Adolescents With ALL

• Status: Unknown status
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

With this protocol the ALL-SCT BFM international study group wants

• to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD).

• to evaluate the efficacy of hematopoietic stem cell transplantation (HSCT)from mismatched family or unrelated donors (MMD) as compared to HSCT from matched sibling donors or matched donors.

• to determine whether therapy has been carried out according to the main HSCT protocol recommendations. The standardisation of the treatment options during HSCT from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only.

• to prospectively evaluate and compare the incidence of acute and chronic Graft-versus-Host-Disease (GvHD) after HSCT from matched sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Anna Kinderkrebsforschung
• Treatments: Etoposide; Etoposide phosphate; Fludarabine; Fludarabine phosphate; Thiotepa; Treosulfan

Criteria

Inclusion Criteria:

• age at time of initial diagnosis or relapse diagnosis, respectively under or equal 18 years

• indication for allogeneic hematopoietic stem cell transplantation(HSCT)

• complete remission before hematopoietic stem cell transplantation (HSCT)

• written consent of the parents (legal guardian) and, if necessary, the minor patient via Informed Consent Form

• no pregnancy

• no secondary malignancy

• no previous hematopoietic stem cell transplantation (HSCT)

• hematopoietic stem cell transplantation (HSCT) is performed in a study participating centre.

Exclusion Criteria:

• age at time of initial diagnosis or relapse diagnosis, respectively above 18 years

• no indication for allogeneic HSCT

• no complete remission before SCT

• no written consent of the parents (legal guardian) and, if necessary, the minor patient via Informed Consent Form

• pregnancy

• secondary malignancy

• previous HSCT

• HSCT is not performed in a study participating centre.